Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

Fig. 5

Genomic and immune correlates in INSPIRE. (a) The frequency of tumor-infiltrating 4-1BB+ PD-1+ CD8 T cells at baseline from fresh tumor biopsies, with representative median flow cytometry staining (b) from patients who achieved a PR or PD as their best response. (c,d) Flow cytometry-based assessment of fold-change in CD4 and CD8 T cells between fresh baseline and on-treatment biopsies. (e-j) Distribution of the measurements with respect to response categories for each factor identified as significantly predictive. P values were determined using the Kruskal-Wallis test. Orange, SCCHN; Pink, TNBC; Purple, HGSC; Red, MM; Blue, MST

Back to article page